Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;84(6):1180-1186.
doi: 10.1111/bcp.13536. Epub 2018 Mar 9.

Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats

Xiaogang Liu  1 , Ye Gu  1 , Yufeng Liu  1 , Mingjing Zhang  1 , Yuting Wang  1 , Liqun Hu  1
Affiliations

Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats

Xiaogang Liu et al. Br J Clin Pharmacol. 2018 Jun.

Abstract

Aims: The full benefits of myocardial revascularization strategies applied to acute myocardial infarction patients might be reduced by myocardial ischaemia and reperfusion (I/R) injury. It is known that inflammation plays an important role in the pathogenesis of I/R injury and galectin-3, a known inflammatory factor, is actively involved in ischaemia-induced inflammation and fibrosis of various organs. Previous studies demonstrated that anti-platelets therapy with ticagrelor, a new P2Y12 receptor antagonist, could effectively attenuate myocardial I/R injury and I/R injury-related inflammatory responses. It remains unknown whether the cardioprotective effects of ticagrelor are also mediated by modulating myocardial galectin-3 expression.

Methods: We determined the ratio of infarct area (IA)/area at risk (AAR), expression of galectin-3, TNF-α and IL-6 in infarct area of rats treated with placebo (equal volume saline per gastric gavage immediately after LAD ligation, then once daily till study end) or ticagrelor (150 mg kg-1 dissolved in saline per gastric gavage immediately after LAD ligation, then once daily till study end) at 24 h, 3 and 7 days post I (45 min)/R injury. Sham-operated rats served as control.

Results: Our results showed that ticagrelor treatment significantly reduced IA/AAR ratio at 3 and 7 days post I/R, downregulated mRNA and protein expression of galectin-3, as well as mRNA expression of TNF-α and IL-6 in infarct area at 24 h, 3 and 7 days post I/R.

Conclusions: Our results suggest that the cardioprotective effects of ticagrelor might partly be mediated by downregulating galectin-3 expression in infarct area in this rat model of myocardial I/R injury.

Keywords: galectin-3; inflammation; ischaemia-reperfusion injury; ticagrelor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ratio of infarct area (IA)/area at risk (AAR). Ticagrelor (black circle) significantly reduced IA/AAR ratio at 3 days and 7 days post I/R injury compared to saline‐treated rats (open circle). IA/AAR ratio was also significantly lower at 3 days and 7 days compared to 24 h in ticagrelor group. ** P < 0.01 vs. placebo group. # P < 0.05 vs. 24 h, ## P < 0.01 vs. 24 h
Figure 2
Figure 2
mRNA expression of galectin‐3 (A), TNF‐ α (B) and IL‐6 (C) in the myocardial tissue of sham group (white bar), placebo group (gray bar) and ticagrelor group (black bar) in infarct area at 24 h, 3 days and 7 days post I/R. * P < 0.05 vs. sham‐operated group; † P < 0.05 vs. placebo group at the same time point; ‡ P < 0.05 vs. 24‐h group within the same treatment group
Figure 3
Figure 3
(A) S1, S3 and S7 represents sham group at 24 h, 3 days and 7 days; P1, P3, P7 represents placebo group at 24 h, 3 days and 7 days; T1, T3, T7 represents ticagrelor group at 24 h, 3 days and 7 days. Representative blot for galectin‐3 of various groups at 24 h, 3 days and 7 days post sham operation or I/R injury. Protein expression of galectin‐3 (B) in the myocardial tissue of sham group (white bar) and infarct area of placebo group (gray bar) and ticagrelor group (black bar) at 24 h, 3 days and 7 days post I/R injury. * P < 0.05 vs. sham‐operated group; † P < 0.05 vs. placebo group at the same time point; ‡ P < 0.05 vs. 24‐h group within the same treatment group
See this image and copyright information in PMC

References

    1. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, et al Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO‐IIb) trial. Circulation 1999; 100: 14–20. - PubMed
    1. Benhabbouche S, Crola da Silva C, Abrial M, Ferrera R. Ann Fr Anesth Reanim 2011). [The basis of ischemia‐reperfusion and myocardial protection]; 30 (Suppl 1): S2–S16. - PubMed
    1. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 2011; 301: H1723–H1741. - PubMed
    1. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31–47. - PubMed
    1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121–1135. - PubMed

Publication types

MeSH terms